University of Texas MD Anderson: Combination Therapy Significantly Improves Survival Outcomes for Patients With Acute Myeloid Leukemia
August 13, 2020
August 13, 2020
HOUSTON, Texas, Aug. 13 -- The University of Texas's MD Anderson Cancer Center issued the following news release on Aug. 12:
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.
The results were presented in the virtual 25th European Hematology Asso . . .
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.
The results were presented in the virtual 25th European Hematology Asso . . .